Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus®): a randomized open-label clinical trial.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2019-0136
Abstract: Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla) and Lantus® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus. Materials & methods: This randomized open-label, 26-week clinical trial enrolled 180 Type 1… read more here.
Keywords: insulin; glargine; efficacy gp40061; safety ... See more keywords